Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32786| Title: | Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. | Authors: | McDonald C.F.;Brodie G.N.;Pretto J.J.;MacGregor D.P.;Goh N.S.L. | Institution: | (Goh) Royal Brompton Hospital, London, United Kingdom (McDonald, Pretto) Department of Respiratory Medicine, Austin and Repatriation Med. Centre, Heidelberg, Vic., Australia (MacGregor) Department of Anatomical Pathology, Austin and Repatriation Med. Centre, Heidelberg, Vic., Australia (Brodie) Department of Medical Oncology, Monash Medical Centre, Clayton, Vic., Australia (McDonald) Department of Respiratory Medicine, HSB, Austin and Repatriation Med. Centre, Studley Road, Heidelberg, Vic. 3084, Australia | Issue Date: | 19-Oct-2012 | Copyright year: | 2003 | Publisher: | Blackwell Publishing (550 Swanston Street, Carlton South VIC 3053, Australia) | Place of publication: | Japan | Publication information: | Respirology. 8 (1) (pp 91-94), 2003. Date of Publication: March 2003. | Abstract: | Langerhans cell histiocytosis (LCH) is a rare disorder which frequently involves the lungs of affected adults. Recent evidence suggests it is a clonal neoplastic disorder. Prognosis in this disease is variable, but in its multisystem form or when associated with progressive respiratory dysfunction, prognosis is poor. Recent case reports and a phase II trial of the antimonocyte drug 2-chlorodeoxyadenosine (2CDA) have described success in treating LCH. We used 2CDA to treat a young Australian man with LCH involving lungs and bone. A complete symptomatic remission was achieved with no evidence of recurrence some 5 years after completion of chemotherapy. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1440-1843.2003.00427.x | PubMed URL: | 12856748 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12856748] | ISSN: | 1323-7799 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/32786 | Type: | Article | Subjects: | etoposide/dt [Drug Therapy] continuous infusion disease course drug tolerability dyspnea/th [Therapy] facies *histiocytosis X/dt [Drug Therapy] human jaw disease lung biopsy lung disease/dt [Drug Therapy] lung function male neutropenia/si [Side Effect] oxygen therapy priority journal remission side effect/si [Side Effect] treatment outcome acepromazine/cb [Drug Combination] acepromazine/dt [Drug Therapy] antineoplastic agent/cb [Drug Combination] antineoplastic agent/dt [Drug Therapy] *cladribine/ae [Adverse Drug Reaction] *cladribine/dt [Drug Therapy] cyclophosphamide/ae [Adverse Drug Reaction] cyclophosphamide/cb [Drug Combination] cyclophosphamide/dt [Drug Therapy] doxorubicin/ae [Adverse Drug Reaction] doxorubicin/cb [Drug Combination] doxorubicin/dt [Drug Therapy] etoposide/ae [Adverse Drug Reaction] etoposide/cb [Drug Combination] cytabom/cb [Drug Combination] cytabom/dt [Drug Therapy] vincristine/dt [Drug Therapy] vincristine/cb [Drug Combination] vincristine/ae [Adverse Drug Reaction] unclassified drug prednisolone/dt [Drug Therapy] prednisolone/cb [Drug Combination] adult alopecia/si [Side Effect] article bone disease/dt [Drug Therapy] case report clinical examination clinical feature computer assisted tomography continuous infusion oxygen therapy priority journal remission side effect / side effect treatment outcome adult alopecia / side effect article bone disease / drug therapy case report clinical examination clinical feature computer assisted tomography disease course drug tolerability dyspnea / therapy facies *histiocytosis X / *drug therapy human jaw disease lung biopsy lung disease / drug therapy lung function male neutropenia / side effect |
Type of Clinical Study or Trial: | Case series or case report |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.